Here are the DEF 14A proxy statements from Myriad Genetics Inc (MYGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MYGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYGN filings page.
Myriad Genetics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026. Proposals include electing three Class III directors, ratifying Ernst & Young as auditor, an advisory vote on executive pay, and approving an amended 2012 Employee Stock Purchase Plan plus a new 2026 equity incentive plan.
In 2025, the company generated $824.5 million in revenue, a 2% decline from 2024, and reported a GAAP net loss of $365.9 million, while producing adjusted EBITDA of $38.9 million and adjusted EPS of $0.06. Total test volumes grew 1%, led by 7% growth in hereditary cancer testing and 6% growth in mental health testing.
The “New Myriad” strategy focuses on the Cancer Care Continuum, with launches planned for the Precise MRD platform, an AI‑enabled Prolaris prostate cancer test and the FirstGene prenatal screen in 2026. Management expects annual revenue growth to accelerate to high‑single‑digit to low‑double‑digit percentages over the mid‑ to long‑term while redirecting and investing more than $35 million into commercial capabilities and key R&D programs.